Trump Pledges To Fast-Track Psychedelic Therapy Research
President Trump signed an executive order mandating the FDA to accelerate the review process for psychedelic-based mental health treatments. This move represents a significant shift in federal approach to treating mental illness with controlled substances. These treatments target veterans suffering from PTSD and traumatic brain injury. The scope of the order also includes depression, anxiety, and substance use disorders. The directive aims to accelerate access to these medical interventions. The order aims to address mental pain and rage in veterans currently reliant on standard VA-prescribed drugs. This represents the first administration-level demand for accelerated research into these treatments. The move targets the long-standing standard of heavy pharmaceutical prescription for veterans.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
“Trump just signed an executive order directing the FDA to fast-track psychedelic treatments for mental illness. The FDA will now cut drug review times from 6-10 months down to 1-2 months.”
“So the order is, so President Trump's order fast tracks promising psychedelic therapies, promising means the ones that we're talking about for veterans with PTSD, with traumatic brain injury, you know, we'll throw in depression, anxiety, substance use disorder.”
“this month's signing of a presidential executive order is groundbreaking. For the first time, an administration is demanding that VA, FDA, and other agencies fast-track serious clinical trials.”
“The FDA has announced it will offer ultra-fast review to two psychedelic drugs, psilocybin and meth alone. And the FDA has authorized initial testing of a drug related to Ibogaine”
“The FDA has announced it will offer ultra-fast review to two psychedelic drugs, psilocybin and meth alone. And the FDA has authorized initial testing of a drug related to Ibogaine for people with alcohol use disorder.”
“follows a White House executive order directing the FDA to speed up”
“Trump as he announced his administration would set aside funding and loosen the bureaucratic process at the FDA to fast-track psychedelic therapy research.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade